Bradley J. Monk
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Retrospective analysis of the QUADRA clinical trial. A, Kaplan–Meier estimation of PFS comparing patients treated with niraparib in the cohort with statin concomitant ( n = 105) and patients not receiving stains ( n = 356); placebo arm was missing; a Cox proportional hazards model using line of therapy, response to last platinum regiment, and HRd status as stratification factors; mPFS, HR, and log-rank test P value are reported. B, Kaplan–Meier estimation of OS comparing patients as described in A . Statin–niraparib combination shows directionally better efficacy than niraparib. OS, overall survival.
Year:
2025
Retrospective analysis of the PRIMA clinical trial in the HRd group. A, Kaplan–Meier estimation of PFS comparing patients classified as HRd treated with niraparib ( n = 49) and placebo ( n = 29) in the cohort with statin concomitant; stratified analysis with three randomization factors (response to first platinum, HRd, status, and neoadjuvant usage); mPFS, HR, and log-rank test P value are reported. B, Kaplan–Meier estimation of PFS comparing patients treated with niraparib ( n = 196) and placebo ( n = 96) in the cohort without statin concomitant. C, Kaplan–Meier estimation of PFS comparing all four arms (the placebo without statins was the reference arm for comparison to the other three arms: niraparib, niraparib + statin, and placebo + statin). D, Kaplan–Meier estimation of PFS comparing niraparib to niraparib + statin arm.
Year:
2025
Retrospective analysis of PRIMA clinical trial in the HRp group. A, Kaplan–Meier estimation of PFS comparing patients classified as HRp treated with niraparib ( n = 33) and placebo ( n = 18) in the cohort with statin concomitant; stratified analysis with three randomization factors (response to first platinum, HRd status, and neoadjuvant usage); mPFS, HR, and log-rank test P value are reported. B, Kaplan–Meier estimation of PFS comparing patients treated with niraparib ( n = 135) and placebo ( n = 61) in the cohort without statin concomitant. C, Kaplan–Meier estimation of PFS comparing all four arms (the placebo without statins was the reference arm for comparison to the other three arms: niraparib, niraparib + statin, and placebo + statin). D, Kaplan–Meier estimation of PFS comparing niraparib to niraparib + statin arm.
Year:
2025
This study investigates the potential clinical synergy between the PARP inhibitor niraparib (Zejula) and concomitant statins, exploring their combined effects on progression-free survival (PFS) in patients with ovarian cancer. We retrospectively analyzed niraparib registrational clinical trials in ovarian cancer to investigate potential interactions between niraparib and statins. In the PRIMA trial, patients receiving niraparib demonstrated improved PFS compared with those on placebo (HR = 0.62; P post hoc analysis revealed that patients receiving maintenance niraparib who reported concomitant use of statins exhibited significantly improved PFS compared with those on placebo with concomitant statins (HR = 0.34; P P = 0.005). These findings suggest novel opportunities in oncology for the use of statins in combination therapies with PARP inhibitors and emphasize the need for further investigation. Significance: The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.
Year:
2025
Retrospective analysis of PRIMA clinical trial–the interaction between niraparib and statin is significant. A, Kaplan–Meier estimation of PFS comparing patients treated with niraparib ( n = 92) and placebo ( n = 51) in the cohort with statin concomitant; stratified analysis with three randomization factors (response to first platinum, HRd status, and neoadjuvant usage); mPFS, HR, and log-rank test P value are reported. B, Kaplan–Meier estimation of PFS comparing patients treated with niraparib ( n = 392) and placebo ( n = 193) in the cohort without statin concomitant. C, Kaplan–Meier estimation of PFS comparing all four arms (the placebo without statins was the reference arm for comparison to the other three arms: niraparib, niraparib + statin, and placebo + statin). Statin and niraparib showed the synergistic combination effect (significant interaction) in this retrospective analysis. No significant differences in baseline characteristics (e.g., age and weight) across groups were observed (Supplementary Table S3). D, Kaplan–Meier estimation of PFS comparing niraparib to niraparib + statin arm.
Year:
2025
Purpose: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). Patients and Methods: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan–Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations between mutation status and outcomes, including PFS and binary response by local RECIST 1.1. Results: MILO/ENGOT-ov11 enrolled 341 patients, ranging in age from 22 to 79, from June, 2013 to April, 2016. Patients were randomized 2:1 to binimetinib or physician's choice of chemotherapy (PCC). The most commonly altered gene was KRAS (33%). In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS ( n = 11, 8.1%), BRAF V600E ( n = 8, 5.9%), RAF1 ( n = 2, 1.5%), and NF1 ( n = 7, 5.2%). In those with and without MAPK pathway alterations, the RRs with binimetinib were 41% and 13%, respectively. PFS was significantly longer in patients with, compared with those without, MAPK pathway alterations treated with binimetinib [HR, 0.5; 95% confidence interval (CI) 0.31–0.79]. There was a nonsignificant trend toward PFS improvement in PCC-treated patients with MAPK pathway alterations compared with those without (HR, 0.82; 95% CI, 0.43–1.59). Conclusions: Although this hypothesis-generating analysis is limited by multiple testing, higher RRs and longer PFS were seen in patients with low-grade serous ovarian cancer (LGSOC) treated with binimetinib, and to a lesser extent in those treated with PCC, who harbored MAPK pathway alterations. Somatic tumor testing should be routinely considered in patients with LGSOC and used as a future stratification factor.
Year:
2025
Purpose: We present the results of a post-hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). Experimental Design: Mutation/copy number analysis was performed on tissue obtained pre-randomization. Kaplan-Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations between mutation status and outcomes, including PFS and binary response by local RECIST 1·1. Results: MILO/ENGOT-ov11 enrolled 341 patients, ranging in age from 22-79, from 6/2013-4/2016. Patients were randomized 2:1 to binimetinib or physician’s choice of chemotherapy (PCC). The most commonly altered gene was KRAS (33%). In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n=11, 8·1%), BRAF V600E (n=8, 5·9%), RAF1 (n=2, 1·5%), and NF1 (n=7, 5·2%). In those with and without MAPK pathway alterations, the RRs with binimetinib were 41% and 13%, respectively. PFS was significantly longer in patients with, compared to those without, MAPK pathway alterations treated with binimetinib (HR 0·5; 95% CI: 0·31, 0·79). There was a nonsignificant trend towards PFS improvement in PPC-treated patients with MAPK pathway alterations compared to those without (HR 0·82; 95% CI: 0·43-1·59). Conclusions: Although this hypothesis-generating analysis is limited by multiple testing, higher RRs and longer PFS were seen in patients with LGSOC treated with binimetinib, and to a lesser extent in those treated with PCC, who harbored MAPK pathway alterations . Somatic tumor testing should be routinely considered in patients with LGSOC and utilized as a future stratification factor.
Year:
2024
PURPOSE To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment. C 40 mg/m 2 and G 50 mg/m 2 were administered once per week throughout IMRT. Complete pathologic response (CPR) was the primary end point. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adverse events were assessed with Common Terminology Criteria for Adverse Events v 4.0. RESULTS Fifty-seven patients enrolled, of which 52 were evaluable. The median age was 58 years (range, 25-58), and 94% were White. Forty (77%) had stage II or III disease, and all had squamous histology. A median of six chemotherapy cycles (range, 1-8) were received. Eighty-five percent of RT plans were quality-reviewed with 100% compliance to protocol. Seven patients came off trial because of toxicity or patient withdrawal. Of 52 patients available for pathologic assessment, 38 (73% [90% CI, 61 to 83]) achieved CPR. No pelvic exenterations were performed. With a median follow-up of 51 months, the 12-month PFS was 74% (90% CI, 62.2 to 82.7) and the 24-month OS was 70% (90% CI, 57 to 79). The most common grade 3 or 4 adverse events were hematologic toxicity and radiation dermatitis. There was one grade 5 event unlikely related to treatment. CONCLUSION Weekly C and G concurrent with IMRT sufficiently improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.
Year:
2024
Purpose: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). Patients and Methods: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan–Meier method was used to estimate progression-free survival (PFS). Unbiased univariate analysis, Cox regression, and binary logistic regression were used to test associations between mutation status and outcomes, including PFS and binary response by local RECIST 1.1. Results: MILO/ENGOT-ov11 enrolled 341 patients, ranging in age from 22 to 79, from June, 2013 to April, 2016. Patients were randomized 2:1 to binimetinib or physician's choice of chemotherapy (PCC). The most commonly altered gene was KRAS (33%). In 135 patients treated with binimetinib with response rate (RR) data, other detected MAPK pathway alterations included: NRAS (n = 11, 8.1%), BRAF V600E (n = 8, 5.9%), RAF1 (n = 2, 1.5%), and NF1 (n = 7, 5.2%). In those with and without MAPK pathway alterations, the RRs with binimetinib were 41% and 13%, respectively. PFS was significantly longer in patients with, compared with those without, MAPK pathway alterations treated with binimetinib [HR, 0.5; 95% confidence interval (CI) 0.31–0.79]. There was a nonsignificant trend toward PFS improvement in PCC-treated patients with MAPK pathway alterations compared with those without (HR, 0.82; 95% CI, 0.43–1.59). Conclusions: Although this hypothesis-generating analysis is limited by multiple testing, higher RRs and longer PFS were seen in patients with low-grade serous ovarian cancer (LGSOC) treated with binimetinib, and to a lesser extent in those treated with PCC, who harbored MAPK pathway alterations. Somatic tumor testing should be routinely considered in patients with LGSOC and used as a future stratification factor.
Year:
2023
Collaborators (14)
Don S. Dizon
Tufts Medical Center
Austin Miller
Asst Professor of Oncology, Biostatistics and Bioinformatics
Roswell Park Comprehensive Cancer Center
isabelle ray coquard
professor
-
Jalid Sehouli
Charité - Universitätsmedizin Berlin
Charles Leath III
The University of Alabama
David S. Miller
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science, Dallas Foundation Chair in Gynecologic Oncology, Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Amit M. Oza
University Health Network
John Farley
Assistant Dean
Creighton University Medical Center
Susana Banerjee
Professor in Women's Cancers (Systemic Therapy and Clinical Trials)
Institute of Cancer Research
Mansoor Mirza
Chief Oncologist
Rigshospitalet
Giovanna Bergamini
Head of Discovery Biology
Cellzome GmbH, a GSK company
David Cibula
Professor M.D
Charles University and General University Hospital in Prague, First Faculty of Medicine
Antonio González-Martín
Co-Director Medical Oncology Department
-
Robert L. Coleman
-
Make your next move.
Prepare your application
Review drafts before you send them.